Cargando…

Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients

The first-line therapy in advanced kidney cancer has changed in recent years due to the introduction of combinations of tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptors (VEGFR) and immune checkpoint inhibitors (ICIs). Although immune-related adverse events are well-k...

Descripción completa

Detalles Bibliográficos
Autores principales: Boutros, Andrea, Vera, Lara, Gatto, Federico, Fornarini, Giuseppe, Zanardi, Elisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755843/
https://www.ncbi.nlm.nih.gov/pubmed/36530979
http://dx.doi.org/10.3389/fonc.2022.1048526
_version_ 1784851509658255360
author Boutros, Andrea
Vera, Lara
Gatto, Federico
Fornarini, Giuseppe
Zanardi, Elisa
author_facet Boutros, Andrea
Vera, Lara
Gatto, Federico
Fornarini, Giuseppe
Zanardi, Elisa
author_sort Boutros, Andrea
collection PubMed
description The first-line therapy in advanced kidney cancer has changed in recent years due to the introduction of combinations of tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptors (VEGFR) and immune checkpoint inhibitors (ICIs). Although immune-related adverse events are well-known, in the case of combination treatments, the determination of which drug is related to an adverse event may be challenging. We reported two cases of patients who developed muscle enzyme elevation in association with hypothyroidism during therapy with pembrolizumab plus axitinib for metastatic kidney cancer. The myopathy rapidly resolved after hormone replacement therapy with levothyroxine. Hypothyroid myopathy is a scarcely known and underreported adverse event. This adverse event may be relevant in the differential diagnosis with immune-related myositis, which has an autoimmune pathogenesis and a potentially fatal course.
format Online
Article
Text
id pubmed-9755843
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97558432022-12-17 Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients Boutros, Andrea Vera, Lara Gatto, Federico Fornarini, Giuseppe Zanardi, Elisa Front Oncol Oncology The first-line therapy in advanced kidney cancer has changed in recent years due to the introduction of combinations of tyrosine kinase inhibitors (TKIs) of vascular endothelial growth factor receptors (VEGFR) and immune checkpoint inhibitors (ICIs). Although immune-related adverse events are well-known, in the case of combination treatments, the determination of which drug is related to an adverse event may be challenging. We reported two cases of patients who developed muscle enzyme elevation in association with hypothyroidism during therapy with pembrolizumab plus axitinib for metastatic kidney cancer. The myopathy rapidly resolved after hormone replacement therapy with levothyroxine. Hypothyroid myopathy is a scarcely known and underreported adverse event. This adverse event may be relevant in the differential diagnosis with immune-related myositis, which has an autoimmune pathogenesis and a potentially fatal course. Frontiers Media S.A. 2022-12-02 /pmc/articles/PMC9755843/ /pubmed/36530979 http://dx.doi.org/10.3389/fonc.2022.1048526 Text en Copyright © 2022 Boutros, Vera, Gatto, Fornarini and Zanardi https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Boutros, Andrea
Vera, Lara
Gatto, Federico
Fornarini, Giuseppe
Zanardi, Elisa
Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
title Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
title_full Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
title_fullStr Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
title_full_unstemmed Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
title_short Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
title_sort case report: pembrolizumab plus axitinib related hypothyroid myopathy in two kidney cancer patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755843/
https://www.ncbi.nlm.nih.gov/pubmed/36530979
http://dx.doi.org/10.3389/fonc.2022.1048526
work_keys_str_mv AT boutrosandrea casereportpembrolizumabplusaxitinibrelatedhypothyroidmyopathyintwokidneycancerpatients
AT veralara casereportpembrolizumabplusaxitinibrelatedhypothyroidmyopathyintwokidneycancerpatients
AT gattofederico casereportpembrolizumabplusaxitinibrelatedhypothyroidmyopathyintwokidneycancerpatients
AT fornarinigiuseppe casereportpembrolizumabplusaxitinibrelatedhypothyroidmyopathyintwokidneycancerpatients
AT zanardielisa casereportpembrolizumabplusaxitinibrelatedhypothyroidmyopathyintwokidneycancerpatients